engleski

Antihyperglycemic action of creatine compared to glibenclamide in type II diabetic patients

Possible involvement of creatine in the regulation of glycaemia in diabetic patients has been implicated. The aim of this study was to investigate the short-term effect of creatine on the glycaemic profile during standard meal in comparison to the oral sulfonylurea hypoglycaemic agent glibenclamide, in type II diabetic patients. In a 14-day simmetrically randomized crossover trial, recently detected type II diabetic patients received either creatine (3 g) or glibenclamide (3.5 mg) for five successive days, followed by two days of washout, and crossover to the opposite treatment. Glucose, insulin, c-peptide, and creatine were measured before, and at 60, 90, 120, 180 and 240 min after a standard meal. Both creatine and glibenclamide decreased glucose concentrations vs. basal glucose [-15, 60, 90, 120, 180, and 240 min ; mmol/l]: 12.6±0.83 vs. 12.2±0.56 vs. 12.1±0.57, 15.3±0.63 vs. 13.5±0.70a vs. 13.0±0.57a, 14.8±0.57 vs. 13.8±0.59a vs. 13.4±0.46a, 14.6±0.61 vs. 12.3±0.49b vs. 12.4±0.61a, 12.8±0.76 vs. 10.0±0.40c vs. 10.3±0.41c, and 11.4±0.67 vs. 8.3±0.40c vs. 8.5±0.36c ; (a p<0.05 ; b p<0.01 ; c p<0.001 vs. basal glucose). Treatment with both creatine and glibenclamide increased insulin and c-peptide concentrations after 120 and 240 min (p<0.05, and p<0.01). Short-term peroral administration of creatine and glibenclamide, at the applied doses, elicits similar glucose lowering action. Relative efficacy of creatine in comparison to glibenclamide remains to be established

creatine; glibenclamide; diabetes; comparison

nije evidentirano